Xencor (NASDAQ:XNCR) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Xencor, Inc. (NASDAQ:XNCR)’s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $13.44 and traded as low as $11.17. Xencor shares last traded at $12.06, with a volume of 1,087,794 shares.

Analyst Upgrades and Downgrades

XNCR has been the subject of several research reports. Barclays lifted their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 target price (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Finally, Wall Street Zen lowered Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.38.

Xencor Trading Up 2.2%

The firm’s fifty day moving average price is $12.01 and its 200-day moving average price is $13.44. The company has a market cap of $939.47 million, a price-to-earnings ratio of -10.33 and a beta of 0.95. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. The business had revenue of $28.24 million for the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The company’s revenue for the quarter was down 46.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.62) EPS. On average, equities analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Buying and Selling at Xencor

In related news, VP John R. Desjarlais sold 2,502 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $11.02, for a total value of $27,572.04. Following the completion of the transaction, the vice president directly owned 263,831 shares of the company’s stock, valued at $2,907,417.62. This represents a 0.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $11.25, for a total value of $36,495.00. Following the completion of the sale, the senior vice president owned 78,685 shares in the company, valued at approximately $885,206.25. This represents a 3.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 44,020 shares of company stock worth $499,817. 4.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Primecap Management Co. CA grew its stake in shares of Xencor by 1.4% in the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after purchasing an additional 147,700 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after purchasing an additional 61,692 shares in the last quarter. BVF Inc. IL lifted its holdings in Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after purchasing an additional 4,393,579 shares during the period. RTW Investments LP lifted its holdings in Xencor by 8.9% in the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after purchasing an additional 556,407 shares during the period. Finally, State Street Corp grew its position in Xencor by 22.7% in the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after buying an additional 833,423 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.